Introducing Dr. Mary-Claire King: Symposium Keynote
We’re excited to share that Dr. Mary-Claire King will be our keynote speaker at the Rivkin Center’s 12th Biennial Ovarian Cancer Research Symposium. Dr. King first discovered BRCA1, the breast and ovarian cancer gene, in 1990. Her work on BRCA1 was a game-changer for how scientists thought about the role of genetics in complex diseases […]
How to Reduce Your Risk for Breast and Ovarian Cancer
In addition to genetics and family history, environment plays a role in breast and ovarian cancer risk. Here are 5 lifestyle behaviors that have been scientifically shown to reduce your risk of ovarian and breast cancer: Be Physically Active — at least 30 minutes per day, 5 days per week Exercise has numerous health benefits, […]
Top 7 Myths About Ovarian and Breast Cancer
Our CanCan parties are a fun, frank way to educate women on ovarian and breast cancer risks and symptoms. They also serve as an opportunity to bust those pesky cancer myths that continue to circulate (but have little or no scientific backing). Curious what questions we get asked the most at CanCan parties? Top Seven Ovarian and […]
Promising news for ovarian cancer treatment with another FDA approval for PARP inhibitors
PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Meet a Rivkin Education Facilitator: Gail Fay
The Rivkin Center’s Education Program The Rivkin Center for Ovarian Cancer’s Education program provides free health education workshops. Rivkin Edu facilitators help educate women about their health, and about their breast and ovarian cancer risks. Say hello to Gail Fay, Rivkin Edu instructor. About Gail Where are you from? Burbank, California Where do you live […]
New Blood Test for Early Detection of 8 Major Cancer Types
Report: New blood test for early detection of 8 major cancer types What does this mean for you? You may have heard the recent hype about a new study in which a blood test was used for the early detection of 8 major cancer types. What does the study really mean and, more importantly, when […]
New study extends benefit of Rucaparib PARP inhibitor to women with BRCA defects in tumors who do not carry inherited BRCA mutations
A study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.
Lucky Cancer
Guest blogger Carol Reed shares the story of when she was diagnosed with ovarian cancer. Each woman’s ovarian cancer story is unique, and Carol emphasizes that she speaks only for herself. This is her experience.
Honoring a very touching gift
Jim Harting left the Rivkin Center the proceeds of the sale of his farm, and the $536,000 gift that Rivkin received this spring as a result of this bequest became one of the largest single gifts in our organization’s history.
An introduction to Rivkin Education
On March 7, the Rivkin Center for Ovarian Cancer merged with CanCan to add ovarian and breast cancer education and awareness as the third component of its programming.